Compare NCPL & VTAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NCPL | VTAK |
|---|---|---|
| Founded | 1984 | 2002 |
| Country | United States | United States |
| Employees | 20 | N/A |
| Industry | Investment Managers | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6M | 3.0M |
| IPO Year | N/A | 2018 |
| Metric | NCPL | VTAK |
|---|---|---|
| Price | $0.43 | $0.98 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 148.7K | ★ 185.9K |
| Earning Date | 03-19-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 89.53 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $442,000.00 |
| Revenue This Year | $739.37 | $1,170.33 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 3057.14 |
| 52 Week Low | $0.31 | $0.15 |
| 52 Week High | $8.75 | $4.31 |
| Indicator | NCPL | VTAK |
|---|---|---|
| Relative Strength Index (RSI) | 49.13 | 42.78 |
| Support Level | $0.37 | $0.15 |
| Resistance Level | $0.60 | $1.28 |
| Average True Range (ATR) | 0.04 | 0.13 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 70.38 | 42.79 |
Netcapital Inc is a financial technology company. The company facilitates the growth of private companies by providing fundraising services and other consulting services. The company's online private investment platform connects entrepreneurs and investors, enabling companies to raise capital digitally. The Company operates in a single operating segment, which is the provision of fintech services.
Catheter Precision Inc is engaged in the design, manufacture, and sale of medical technologies focused in the field of cardiac electrophysiology, or EP. The company's two primary products include the VIVO System and LockeT. The VIVO System, which is an acronym for View into Ventricular Onset System(VIVO or VIVO System), is a non-invasive imaging system that offers 3D cardiac mapping to help with localizing the sites of origin of idiopathic ventricular arrhythmias in patients with structurally normal hearts prior to EP procedures. Its newest product, LockeT, is a suture retention device indicated for wound healing by distributing suture tension over a larger area in the patient in conjunction with a figure of eight suture closure.